Who Paid My Doc
Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneously SC in adult participants with symptomatic COPD and history of 2 moderate or 1 severe exacerbation of COPD in the previous 12 months
Research payments
$4,645,490
Through program year 2024, $4,645,490 in research payments was reported against Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneously SC in adult participants with symptomatic COPD and history of 2 moderate or 1 severe exacerbation of COPD in the previous 12 months, across 184 payments.
- Paid by (largest first)
- AstraZeneca UK Limited; AstraZeneca Pharmaceuticals LP
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $1,145,233 | 51 |
| 2023 | Research | $2,369,354 | 87 |
| 2022 | Research | $1,130,902 | 46 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Rodolfo Trejo Lake Worth, FL Named on 6 payments
- David Bernard Yonkers, NY Named on 5 payments
- Richard Beasley Rapid City, SD Named on 5 payments
- Frank Sciurba Pittsburgh, PA Named on 5 payments
- Dareen Siri Normal, IL Named on 5 payments
- Aaron Milstone Franklin, TN Named on 5 payments
- Ernest Thompson Baker, LA Named on 5 payments
- Eric Boren Delano, CA Named on 4 payments
- Mikell Jarratt Gastonia, NC Named on 4 payments
- Sanjay Sikand Brick, NJ Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.